NEULAND
WHERE OPPORTUNITY BECOMES REALITY

Neuland Laboratories Limited
Sanali Info Park, 'A' Block,
Ground Floor, 8-2-120/113
Road No. 2, Banjara Hills
Hyderabad - 500 034.
Telangana, India.

Tel: 040 30211600 / 23551081
Fax: 040 30211602
Email: neuland@neulandlabs.com
www.neulandlabs.com

May 7, 2020

To
BSE Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai – 400 001

Scrip Code: 524558

To
The National Stock Exchange of India Ltd
Exchange Plaza,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 001

Scrip Code: NEULANDLAB; Series: EQ

Dear Sirs,

Ref: Our letter dated February 7, 2020 on United States Food and Drug Administration (U.S.FDA) inspection at our Unit 2 manufacturing facility at Pashamylaram, Hyderabad.

We refer to our letter dated February 7, 2020 and would like to inform you that the Company has received an Establishment Inspection Report (EIR) from the U.S.FDA for its manufacturing facility located at Pashamylaram, Hyderabad. The facility was inspected from 3rd to 7th February 2020. The inspection has now been closed by the U.S. FDA.

This is for your information and records.

Yours faithfully,

For **Neuland Laboratories Limited**

Sarada Bhamidipati

Digitally signed by Sarada Bhamidipati
DN: cn=Sarada Bhamidipati, o=Neuland Laboratories Limited, ou, email=saradab@neulandlabs.com, c=IN
Date: 2020.05.07 21:12:31 +05'30'

Sarada Bhamidipati
Company Secretary & Compliance Officer